Abstract: Multi-step continuous flow synthesis enables a parallel approach to obtain agrochemicals and pharmaceuticals containing 3-fluoroalkyl pyrazole cores. In this system, fluorinated amines are transformed into pyrazole cores through a telescoped in situ generation and consumption of diazoalkanes. Once synthesized, additional continuous flow and batch reactions add complexity to the pyrazole core via C-N arylation and
Introduction
Continuous flow has emerged as an enabling technology in organic synthesis over the last decade.
[1] The growth of continuous flow can be credited to its benefits over batch chemistry. In continuous flow systems, solvents and reactants can be heated above their atmospheric boiling points to afford improved kinetics, [2] hazardous reactions can be confined to small volume reactor coils for improved safety, [1e,3] and reaction scale can be addressed through parallel processing to meet a demand. [4] In multi-step continuous flow synthesis, sequential reactor coils are used to accrue molecular complexity. [1a,1f ] While a large number of valuable multi-step continuous flow syntheses exist, only a few can be considered modular, or "assembly line processes".
[5] The concept of assembly lines originates from Henry Ford's achievements in the motor industry. Here, simple frameworks are passed along a conveyer belt where additional pieces are installed in a specific order to create a car. In a continuous flow sense, passing molecules through specific reactor modules dictates the chemical functionality present in the final product. Additionally, modules often have broad substrate compatibility, and reconfiguring the sequence of modules can enable the synthesis of different target compounds. After recently achieving an assembly line synthesis of Measles therapeutic AS-136A through this approach, we hypothesized that several other bioactive molecules could benefit. [6] In our initial communication, six continuous flow modules were reported that mediate diazoalkane formation, [3+2] cyclo-1 methylation, TMS cleavage, and amidation. Using this modular assembly line approach, Bixafen and Fluxapyroxad were synthesized in 38 % yield over four continuous flow steps in an overall reaction time of 56 min. Finally, coupling selected continuous flow processes with an offline (batch) Ullmann coupling afforded Celecoxib, Mavacoxib, and SC-560 in 33-54 % yield over two to three steps. addition, C-N arylation, C-N methylation, TMS removal and amidation. [6] Herein, these continuous flow modules are further optimized and subsequently utilized to rapidly synthesize popular agrochemicals Fluxapyroxad and Bixafen, [7] and coupling continuous flow and batch techniques allowed a parallel synthesis of non-steroidal anti-inflammatory drugs (NSAIDs) Celecoxib (Celebrex™), [8] Mavacoxib (Trocoxil™), [9] and SC-560 [8, 10] (Figure 1 ). Furthermore, the discovery of a radical pathway for the synthesis of a symmetrical vinyl ether, and a lipase-catalyzed hydrolysis of a pyrazole ester is disclosed. In an assembly line synthesis, each reactor module performs a dedicated transformation that is part of an overall sequence. To enable the parallel synthesis of a range of pyrazole products, the initial modules in the sequence create the desired pyrazole core from readily available commercial building blocks. Once the pyrazole core has been generated, subsequent modules modify and augment the substituents appended to these cores to generate the molecule of interest (Figure 2 ). The structure of pyrazole product is controlled by the type and sequence of modules installed in the assembly line and the starting materials supplied to the system. In building upon our previous work, module 1 rapidly creates diazoalkanes that are immediately consumed in a [3+2] cycloaddition with an alkyne in module 2 to generate pyrazole cores. A range of additional modules then modify this core, including module 3 that mediates C-N arylation, module 4 that mediates C-N methylation, module 5 that mediates TMS-cleavage, and module 6 that mediates amidation ( Figure 2 ). In this work, orientation of the modules in the order: 1, 2, 5, 4, and then 6 enabled parallel syntheses of Fluxapyroxad and Bixafen (Figure 2 , Route C). While replacing modules 5, 4, and 6 with an offline Ullmann coupling generated Celecoxib, Mavacoxib, and SC-560 in a parallel fashion (Figure 2 , Route D). For convenience, each module is described individually below. Here, route C is used to synthesize two agrochemicals, and route D is used to synthesize three pharmaceuticals.
(i) Module 1 and 2: Making the Pyrazole Core
In this assembly line process, common pyrazole cores are constructed through [3+2] cycloaddition between 2,2-difluoro-methyl diazomethane 1, or 2,2,2-trifluoromethyl diazomethane 2 with an alkyne (Figure 3 ). In optimizing this transformation, 1 was synthesized in situ for immediate consumption in a [3+2] cycloaddition with ethyl propiolate. The synthesis of 1 (Module 1) requires only 5 min at 60°C ( Figure 3B and D), and [2+3] cycloaddition (Module 2) requires only 10 min at 90°C ( Figure 3C and E). Interestingly, any deviation away from these optimal reaction conditions significantly decreased the yield. For example, increasing the temperature of module 1 passed 60°C results in lower yields due to diazoalkane and tBuONO decomposition ( Figure 3B) , [11] while operating module 2 passed 90°C lead to rapid gas evolution with concomitant lower yields ( Figure 3C ). With these optimized conditions, 3 and 4 were afforded in 92 % and 99 % yields respectively. Using TMS-protected alkynes in module 2 affords pyrazoles with electron withdrawing functionality at the 4-position (Table 1 and Table 2 , 5-8). However, applying the general conditions above for the synthesis of 5 yielded only 44 % (Table 1 , Entry 1). Analysis of the reaction mixture led to the isolation of both 5 and 3. While 5 is formed through [3+2] cycloaddition between 1 and the TMS-alkyne, 3 is formed due to TMS cleavage by AcOH prior to cycloaddition, leading to the electronically favored isomer 3. To avoid TMS cleavage, the concentration of AcOH was reduced to 10 %, and the alkyne operated in twofold excess relative to the amine. With these conditions, 5 was afforded in 59 % yield and 100 % selectivity, and 6 in 72 % yield, and 76 % selectivity (Table 1, Entry 5). However, synthesizing the CF 3 analogue 7 with these new conditions lead to only 2 % yield, while initial conditions yielded only 21 % (Table 2 , Entry 1 and 2). Re-optimization revealed that a fourfold excess of both 2,2,2-trifluoroethylamine and tBuONO with 15 % AcOH was necessary for high yields and selectivity (Table 2, Entry 6). With these conditions, 7 was afforded in 70 % yield and 85 % selectivity, and 8 in 67 % yield, and 88 % selectivity. This delicate optimization process revealed that when using substrates containing CF 3 or CF 2 H moieties, minor alterations may be required to ensure both good yield and selectivity. Adding a new pyrazole core to the assembly line library simply requires validating, and if necessary, re-optimizing, the conditions employed in modules 1 and 2. [a] Average isolated yield (n = 2). In this optimization, the concentration of AcOH and the ratio of reagents were varied for high selectivity and yield. For a list of additional pyrazoles synthesized, see previous work. [6] [a] Average isolated yield (n = 2). In this optimization, the concentration of AcOH and the ratio of reagents were varied for high selectivity and yield. For a list of additional pyrazoles synthesized, see previous work.
[ 6] Eur. During optimization, we found that replacing fluoroamines (CF 2 RCH 2 NH 2 ) with Et 3 N, generated symmetrical divinyl ether 9 in quantitative yield under identical conditions ( Figure 4A ). Several control reactions revealed that this is likely the product of a radical chain process: First, reacting ethyl propiolate and tBuONO under identical conditions, but devoid of Et 3 N, yielded 0 %, and returned only starting material. Second, removing tBuONO from the reaction mixture yielded 0 %, revealing that both Et 3 N and tBuONO are required for the generation of 9. Next, adding stoichiometric TEMPO to the reaction mixture decreased the yield to 86 %, indicating a possible radical pathway. Finally, sparging solutions with argon prior to the reaction to remove dissolved O 2 led to 9 still being generated in quantitative yields. This final result indicates that the vinyl oxygen atom present in 9 most likely comes from tBuONO. To explain this unusual transformation, we propose the following mechanism. First, heating tBuONO generates a tBuO · radical that adds across the alkyne generating a vinyl centered radical ( Figure 4B , step i).
[12] After proton abstraction from the pendant tBu group, a terminal O · radical is generated that can propagate onto another molecule of ethyl propiolate ( Figure 4B , steps ii-iii). After propagation, Et 3 N behaves as a proton donor to afford 9 ( Figure 4B , steps iv-v). Interestingly, this reaction requires 40 % AcOH to achieve high yields as running the reaction devoid of AcOH affords only 31 % yield. We believe that AcOH maybe activating tBuONO towards bond homolysis. To test this hypothesis, the reaction temperature was reduced to 40°C (below the typical decomposition temperature of tBuONO [12b] ), and 9 was still afforded in 95 % yield. At this stage, a radical pathway seems likely, but a two-electron mechanism cannot be ruled out before additional studies.
(ii) Module 3: C-N Arylation
Our initial communication briefly detailed a continuous flow C-N arylation through a Cu(OAc) 2 catalyzed Chan-Lam-Evans coupling. For optimization of this reaction, high throughput screening of reaction conditions was performed in a batch microwave reactor (Table 3) . Screening reactions under microwave conditions prior to translation into continuous flow has several benefits. First, solid formation in a microwave vial is less likely to cause problems; in continuous flow, solid formation can lead to reactor failure. Second, commercial microwave reactors allow reaction automation; a feature not currently readily available in continuous flow reactors. Third, less material is used in a microwave reaction, as microwave processes do not require equilibration. Finally, once optimized, translating into continuous flow can have additional benefits including reduced solvent vaporization and enhanced mixing.
Initially, reacting 4 with phenylboronic acid at 90°C for 60 min with Et 3 N and pyridine afforded 10 in 31 % yield (Table 3 , Entry 1). Through optimization of reaction temperature, solvent, concentration of 4 and Et 3 N, we found that performing the reaction devoid of Et 3 N and with a low concentration of 4 was vital (45 % yield, Table 3 , Entry 4). Furthermore, addition of an external oxidant such as TEMPO, or conducting the reaction under an atmosphere of O 2 had no benefit (Table 3, Entry 4). With these conditions, the reaction was translated into continuous flow to obtain a 49 % yield (Table 3 , Entry 7). To increase the yield of 10 to 66 %, it was crucial to use 4 in low concentrations, and in twofold excess relative to phenylboronic acid (Table 3 , Entry 8); we hypothesize that 4 is a competitive ligand, and its use as the rate-limiting reagent will always generate low yields. Finally, reducing the loading of Cu(OAc) 2 to 20 % and adding one equivalent of TEMPO afforded 10 in 42 % yield, indicating a catalytic approach may be possible in future work.
Although Cu(OAc) 2 catalyzed C-N arylation generated 10 in good yield, these conditions were not successful for pyrazoles 11 and 12; <11 % yields were obtained in both cases ( Figure 5 ). We hypothesize that the increased sterics of 11 and 12 lead to the requirement for longer reaction times and more forcing conditions. Indeed, recent reports require heating the reaction mixture at 150°C for 36 h with catalytic CuI (5 mol-%), K 2 CO 3 , and diamine ligand (20 mol-%).
[13] Thus, to furnish SC-560, Mavacoxib, and Celecoxib in good yield, batch Ullman couplings were performed. For the synthesis of SC-560 17, pyrazole 15 was first synthesized in modules 1 and 2 (76 %, 32 min) [6] before an Ullmann coupling with 4-iodoanisole (24 h, 150°C). Under these conditions, the human lung, breast, and colon cancer suppression candidate 17 was afforded in 70 % yield ( Figure 6A ).
[10]
Figure 5. C-N arylated products using the optimized conditions described in Table 3 . To note is that pyrazoles 11, 12, 15, and 16 are synthesized via modules 1 and 2 as per our previous report. For the synthesis of Mavacoxib 18 and Celecoxib 19, sulfonamide 20 is required as the coupling partner. To aid in the synthesis of both Celecoxib and Mavacoxib, the synthesis of 20 was translated to a continuous flow system. Here, reacting 4-iodobenzenesulfanoylchloride with dibenzylamine for 6.7 min generated 20 in quantitative yield at 9.3 g h -1 ( Figure 6B ). Additionally, an in line quench and extraction allowed purified 20 to be generated in 73 % yield at 6.8 g h -1
. Next, pyrazoles 15 and 16 were synthesized in modules 1 and 2 (76 % yield, 32 min) [6] before Ullmann couplings with 20 (24 h, 150°C) furnished the protected forms of Mavacoxib and Celecoxib. To reveal the bioactive compounds, deprotection with conc. H 2 SO 4 afforded Mavacoxib 18 and Celecoxib 19 in 43 % and 71 % yield respectively ( Figure 6B ). In concluding this module, combining continuous flow and batch chemistry allows efficient access to several bioactive molecules in a parallel fashion. Here, Ullmann couplings were performed in batch due to their long reaction times (24 h). Development of a more continuous flow friendly process would be highly desirable.
(iii) Module 4: C-N Methylation
Several of the APIs and agrochemicals require C-N methylation at the N 1 position. In previous syntheses, methylation is achieved by using iodomethane (MeI) and K 2 CO 3 . [14] The use of heterogeneous reaction mixtures in continuous flow, however, is not ideal. To overcome this, several organic bases were screened for the methylation of 4 under microwave conditions. Of the bases tested (Et 3 N, DABCO, Hünig's base) tetramethylpiperidine (TMP) at 120°C for 30 min afforded 21 in 99 % yield (Table 4 , Entry 2). Additionally, reducing the reaction time to one min under the same conditions afforded 21 in 80 % yield (Table 4 , Entry 3), while at 22°C only 64 % was obtained (Table 4 , Entry 4). Next, several mixtures of DMF and DCM were tested to simulate the conditions expected during reaction telescoping with modules 1 and 2. While a 75:25 mixture of DMF/ DCM for one min at 90°C afforded 21 in 65 % yield (Table 4 , Entry 5), pure DCM under the same conditions afforded only 6 % yield (Table 4, Entry 8).
Next, CF 2 H pyrazole 3 was tested, but only a 29 % yield of 22 was obtained. We hypothesize that the acidity of the CF 2 H proton leads to additional and unwanted reactivity. In exploring reaction conditions for both CF 2 H, and CF 3 pyrazoles, DBU was found to yield > 99 % and 85 % respectively (Table 4 , Entries 9 and 10). Translating optimized conditions from microwave experiments to a single continuous flow set up with DBU provided satisfactory conditions for methylating both CF 2 H and CF 3 analogues in 94 % and 79 % yield respectively (Table 4 , Entry 11 and 12). Lastly, translating into the multi-step continuous flow system (Table 4 , Scheme B) with an extended reaction time of 27.6 min and increasing to five equivalents of MeI and DBU, 21 and 22 were yielded in 81 % and 75 % respectively (Table 4 , Entries 13 and 14). Another benefit of this multi-step system was the ability to avoid MeI decomposition in DMF. Pre-diluting MeI with DMF leads to slow generation (> 30 min) of a yellow solution; MeI reacts with DBU releasing iodide. To avoid this, neat MeI and DMF from the supplier's bottle were diluted in situ to create the correct concentration prior to entering the system. To further highlight this point, premixing MeI and DBU in DMF and loading into an 8 mL stainless steel syringe for elution over a 8 h period at 12.5 μL min -1 leads to no methylation of 3, and returns only starting material.
When methylating CF 3 bearing pyrazoles, only the N 1 methylated pyrazole was observed. However, when methylating CF 2 H containing pyrazole 3, a ≈ 8:2 mixture of N 1 and N 2 methylated regioisomers was obtained. With the methylation of difluoro analogue 22 required for the synthesis of Fluxapyroxad and Bixafen (Figure 1) , we found conditions to separate the regioisomers by column chromatography on silica. In this case, methylating 22 yields a 62:38 mixture of N 1 and N 2 regioisomers (22A and 22B, Figure 7 ).
(iv) Module 5: TMS Removal
To afford ester functionality at the 4-position of the pyrazole core (5-8), TMS-protected alkynes are used to alter the regiochemical outcome of the cycloaddition in module 2. For the final targets, however, TMS cleavage is required. This module required fine optimization to achieve TMS removal in the presence of CF 2 H groups, again highlighting the different conditions required for CF 3 and CF 2 H functionalities. First, TMS cleavage of 8 was explored under microwave conditions. Inspired by previous reports [15] heating at 150°C for 30 min with two equivalents of KOH yielded 24 in 68 % yield. However, when these conditions were tested for TMS cleavage of 6, 0 % yield resulted. TLC analysis of the crude reaction mixture revealed full consumption of starting material, while 1 H NMR indicated that no CF 2 H group was present. In exploring new deprotection strategies, the use of 2.4 equivalents of tetrabutylammonium fluoride (TBAF) buffered with equimolar AcOH was suitable. Under these conditions, 24 was afforded in 74 % yield (Table 5 , Entry 2), while lowering the concentration of TBAF and AcOH to 1.75 equivalents lead to 96 % (Table 5 , Entry 3). Furthermore, when using CF 2 H analogue 6, an 84 % yield of 23 was obtained (Table 5 , Entry 5). To note, not buffering with AcOH lead to decomposition of 6, and testing fluoride on polymer support (Sigma, 20-50 mesh, 2-3 mmol/g loading) showed no reactivity with 6. [a] Yields were determined through 1 H analysis with anisole (5.8 μL, 0.05 mmol).
[b] Yield determined through 1 H analysis with α,α,α-trifluorotoluene (30.0 μL, 0.246 mmol).
(v) Module 6: Amidation
For many targets, amidation reveals the final bioactive structures. First, direct amidation of the pyrazole ester was attempted using high temperature microwave conditions. Using DMF as the solvent, a 2:1 ratio of 4-fluoroaniline: 21 at 170°C for 30 min resulted in no reactivity. To overcome this, our previous approach using LiHMDS was used. [6, 16] Given the eventual telescoped nature of this process, the solvent was switched from DCM to DMF; an excellent 94 % yield was still obtained (Table 6 , Entry 2). Next, while reducing the residence time to 2.5 min gave quantitative yields, a one min residence time afforded 83 % (Table 6 , Entries 3-4). To overcome this drop in yield, the reactor coil was heated to 40°C to afford 35 in 93 % isolated yield (Table 6 , Entry 5). Notably, the 1 M LiHMDS in THF was used directly from the supplier's bottle by interfacing the inlet feed of the stainless steel syringe to a needle, which is then attached to commercial LiHMDS using standard syringe techniques. This generalizable flow approach avoids user exposure to this flammable and toxic chemical.
With amidation optimized, the synthesis of agrochemicals Fluxapyroxad and Bixafen was achieved. First, the amines required for generating Fluxapyroxad and Bixafen were synthe- sized through a multi-gram Suzuki cross couplings in batch; both proceeded in > 90 % yield (26 and 27, Figure 8A ). Next, N 1 methylated pyrazole 22A was treated with both 26 and 27 to afford Fluxapyroxad 28 and Bixafen 29 in 96 % yield (Figure 8B) in 90 % and 99 % respectively ( Figure 8B ). In conclusion, Fluxapyroxad and Bixafen have been synthesized in 38 % overall yield through using five different continuous flow modules (two of which are telescoped) for an overall reaction time of only 56 min. To further extend the utility of this process, their N 2 regioisomers were also synthesized to demonstrate the parallel nature of this assembly line synthesis.
(vi) Enzymatic Hydrolysis of Pyrazole Ester 4
Pyrazole ester hydrolysis is currently the major pathway to generate the required amides. Typically, 1 M NaOH hydrolyzes the ester, 6 M HCl generates the free acid, and SOCl 2 activates the acid for amidation. [13b,17] With interests in developing additional methods for manipulating pyrazoles, enzymatic hydrolysis with an immobilized lipase was explored (Figure 9 ). Dissolving 4 in Figure 9 . Enzymatic hydrolysis of 4 to yield free acid 32 with immobilized CAL-B lipase.
DMSO and diluting with PBS buffer at pH 7 provided a homogeneous solution (96 μmol in 99:1 H 2 O/DMSO) suitable for hydrolysis with immobilized CAL-B lipase (Candida antarctica recombinant from Aspergillus oryzae). Simply stirring the solution for 8 h at 40°C, and filtering off the immobilized lipase provided 32 in 75 % yield. In demonstrating the utility of this reaction, the transformation was performed on an 800 mg scale; 32 was afforded in 37 % isolated yield. This simple enzymatic hydrolysis adds a useful tool of this assembly line sequence that importantly removes the need for concentrated HCL and NaOH.
Conclusions
Using the concept of an assembly line, five bioactive molecules have been synthesized in a parallel fashion. Using six continuous flow, and one batch reactor, low cost fluorinated amines are transformed into agrochemicals and pharmaceuticals in short order. The success of this system stems from the ability of the continuous flow modules to operate solvents and reagents above their atmospheric boiling points, and safely process toxic and explosive intermediates. Using five different continuous flow modules (four individual continuous flow processes), Bixafen and Fluxapyroxad were synthesized in a 38 % overall yield. Additionally, coupling a telescoped continuous flow process with an Ullmann coupling in batch provided access to SC-560, Celecoxib, and Mavacoxib in 43-70 % yield over 2-3 steps. The ability to synthesize many bioactive molecules by modifying a common core opens up the possibility for generating compound libraries for medicinal chemistry. Additionally, as many natural products contain the same core functionality, we envisage the ability to create families of natural products through a similar assembly line process.
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